CAM
NTLA icon

Cresset Asset Management’s Intellia Therapeutics NTLA Stock Holding History

Cresset Asset Management’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-24,206
Closed -$497K – 2065
2024
Q3 		$497K Sell
24,206
-4,487
-16% -$103K ﹤0.01% 1521
2024
Q2 		$642K Buy
28,693
+3,313
+13% +$78.9K ﹤0.01% 1322
2024
Q1 		$698K Buy
25,380
+2,803
+12% +$77.9K ﹤0.01% 1172
2023
Q4 		$688K Buy
22,577
+2,329
+12% +$66.9K ﹤0.01% 1056
2023
Q3 		$640K Buy
20,248
+503
+3% +$19.5K ﹤0.01% 1052
2023
Q2 		$805K Buy
+19,745
New +$801K ﹤0.01% 1048
2022
Q2 		– Sell
-13,783
Closed -$1M – 1045
2022
Q1 		$1M Sell
13,783
-1,587
-10% -$134K 0.01% 406
2021
Q4 		$1.82M Sell
15,370
-29,873
-66% -$3.74M 0.02% 317
2021
Q3 		$6.07M Sell
45,243
-4,161
-8% -$630K 0.08% 99
2021
Q2 		$8M Sell
49,404
-7,032
-12% -$548K 0.11% 68
2021
Q1 		$4.53M Buy
56,436
+24,224
+75% +$1.63M 0.07% 96
2020
Q4 		$1.75M Buy
32,212
+2,081
+7% +$75.6K 0.03% 176
2020
Q3 		$599K Buy
30,131
+14,428
+92% +$301K 0.01% 346
2020
Q2 		$330K Buy
+15,703
New +$267K 0.01% 431

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $47.9M AUM 29.29% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Cresset Asset Management's NTLA Position: Q4 2024 in Review

Cresset Asset Management sold out of Intellia Therapeutics (NTLA) in Q4 2024, closing a stake of 24,206 shares — an estimated $497K sold.

Cresset Asset Management first reported a position in NTLA in Q2 2020 and held it in 14 quarters. The position peaked at $8M in Q2 2021. 293 funds tracked by Wall St. Rank hold NTLA as of Q4 2024.

  • Cresset Asset Management reported no remaining Intellia Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Cresset Asset Management sold 24,206 Intellia Therapeutics shares in Q4 2024, an estimated $497K.
  • Cresset Asset Management first reported a position in Intellia Therapeutics in Q2 2020 and held it in 14 quarters.
  • Cresset Asset Management's Intellia Therapeutics position peaked at $8M in Q2 2021.
  • 293 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q4 2024.

Based on Cresset Asset Management's 13F filing for Q4 2024, filed 14 Feb 2025.